Published in Cancer Weekly, November 1st, 2005
The approval was based on the Intergroup Exemestane Study (IES) which showed that patients who switched to Aromasin after 2-3 years of tamoxifen, for a combined total of 5 years of therapy, had 31% more protection from cancer recurrence than those who remained on 5 years of tamoxifen therapy.
This landmark study, published in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.